[The risk/benefit profile of biologic drugs in real-world rheumatology practice. From ANTARES to MonitorNet].

Le principali artriti croniche ad eziopatogenesi immunoflogistica, nelle quali trovano applicazione i farmaci “biologici” (v. oltre) sono la reumatoide e le sieronegative: artrite psoriasica, spondilite anchilosante, artriti reattive ed artriti “enteropatiche” (1-7). L’artrite reumatoide (AR) e una malattia cronica progressiva delle articolazioni associata a significativa morbilita, deformita e riduzione della qualita di vita. La prevalenza nella popolazione, a livello mondiale, e compresa tra 0,3 ed 1%. Pur interessando in modo elettivo le articolazioni, l’AR e una malattia sistemica che puo condurre a severa disabilita ed a complicanze talora fatali. La terapia farmacologica tradizionale si basa su varie combinazioni di farmaci definiti sintomatici, come gli anti-infiammatori non-steroidei (FANS), gli analgesici ed i corticosteroidi e quelli “di fondo” chiamati correntemente DMARDs (disease modifying anti-rheumatic drugs)...

[1]  L. Jacobsson,et al.  Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register , 2008, Annals of the rheumatic diseases.

[2]  J. Askling,et al.  Malignancy and biologic therapy in rheumatoid arthritis , 2008, Current opinion in rheumatology.

[3]  M. Weisman,et al.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 , 2007, Annals of the rheumatic diseases.

[4]  L. Punzi,et al.  Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis. , 2007, Autoimmunity reviews.

[5]  H. H. Kuper,et al.  The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice , 2007, Annals of the rheumatic diseases.

[6]  W. Rigby.  Drug Insight: different mechanisms of action of tumor necrosis factor antagonists—passive-aggressive behavior? , 2007, Nature Clinical Practice Rheumatology.

[7]  R. Caporali,et al.  High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor α inhibitors in rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[8]  L. Punzi,et al.  [Antinuclear, anti-dsDNA and anti-ENA antibodies in patients affected with rheumatoid arthritis or ankylosing spondylitis during treatment with infliximab]. , 2011, Reumatismo.

[9]  L. Klareskog,et al.  Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case–control study , 2006, Annals of the rheumatic diseases.

[10]  G. Kingsley,et al.  Tumor necrosis factor inhibitors for rheumatoid arthritis. , 2006, The New England journal of medicine.

[11]  M. Cutolo,et al.  Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy. , 2006, Clinical and experimental rheumatology.

[12]  R. Straub,et al.  Anti‐TNF and Sex Hormones , 2006, Annals of the New York Academy of Sciences.

[13]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[14]  A. Iliadou,et al.  Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[15]  E. Keystone,et al.  Musculoskeletal manifestations and autoimmune diseases related to new biologic agents , 2006, Current opinion in rheumatology.

[16]  M. Dougados,et al.  First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis , 2005, Annals of the rheumatic diseases.

[17]  I. Olivieri,et al.  Recommendations of the Italian Society for Rheumatology for the use of biologic (TNF-alpha blocking) agents in the treatment of psoriatic arthritis. , 2006, Clinical and experimental rheumatology.

[18]  S. Todesco,et al.  [Incidence and management of infusion reactions to infliximab in 186 italian patients with rheumatoid arthritis: the Padua experience]. , 2011, Reumatismo.

[19]  M. Wallace,et al.  Infections Associated With Tumor Necrosis Factor-α Antagonists , 2005 .

[20]  P. Sarzi-Puttini,et al.  Autoimmunity and Anti‐TNF‐α Agents , 2005 .

[21]  M. Lebwohl,et al.  The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. , 2005, Seminars in arthritis and rheumatism.

[22]  C. Botsios.  Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. , 2005, Autoimmunity reviews.

[23]  M. Turiel,et al.  Autoimmunity and anti-TNF-alpha agents. , 2005, Annals of the New York Academy of Sciences.

[24]  M. Wallace,et al.  Infections associated with tumor necrosis factor-alpha antagonists. , 2005, Medicine.

[25]  L. Punzi,et al.  Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate , 2003, Annals of the rheumatic diseases.